Figure 2

Chase of the minor BCR-ABL1 positive clone during clinical course. (A) FACS analysis and sorting of BMMCs at four weeks after the initiation of dasatinib treatment. The gating strategy to isolate three populations is shown. Lineage markers include CD2, CD3, CD4, CD7, CD8, CD11b, CD14, CD56 and CD235. (B) RT-PCR analysis for each population (gated in (A)) at four weeks and bulk BMMCs at ten weeks. Minor BCR-ABL transcripts was clearly detected only in CD34⁺CD19⁺ cells but not in CD34⁺CD19^- at four weeks and still detected in bulk BMMCs in low levels at ten weeks. Positive control (PC), plasmids containing the amplified region of minor BCR-ABL or the GAPDH gene; negative control (NC), distilled water.